VITRUVIAE
Nutley
About VITRUVIAE
VITRUVIAE is an early-stage biotechnology company focused on developing innovative pan-drug solutions to treat cancer and virus drug resistance. The company’s lead biotherapeutic, VTRU200, targets aberrant sugar and lipid signatures on viruses and cancers. VITRUVIAE employs a unique approach by targeting specific signatures not present in normal cells, encoded by mRNA, to aid medical professionals in treatment. The company aims to restore quality of life through its revolutionary biotherapeutic solutions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $75.0K
- Last round: Grant (Mar 2025)
- Website: vitruviae.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vitruviae-110194 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.